MAP2K1 and neoplasm: The authors confirm inter-tumour heterogeneity amongst distinct metastases of a single patient and identify three independent BRAF amplification events, a novel aberrant form of BRAFV600E that contains an unknown N-terminus, and a novel MEK1 mutation, which was detected in two out of five metastases.